ClinicalTrials.gg
Active, not recruitingNCT00445367Updated Oct 27, 2026

Biobank For MS And Other Demyelinating Diseases

An observational study in Multiple Sclerosis, Transverse Myelitis and Neuromyelitis Optica, sponsored by Accelerated Cure Project for Multiple Sclerosis. Active, not recruiting at 10 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Accelerated Cure Project for Multiple Sclerosis · Observational

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
3,226
Sex
All
01

Study summary

To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.

02

Conditions studied

  • Multiple Sclerosis
  • Transverse Myelitis
  • Neuromyelitis Optica
  • Acute Disseminated Encephalomyelitis
  • Optic Neuritis

Keywords

  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Transverse Myelitis
  • Neuromyelitis Optica
  • Acute Disseminated Encephalomyelitis
  • Optic Neuritis
  • Repository
  • Biobank
03

In context

Multiple Sclerosis

3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.

This study's enrollment of 3,226 is above the median of 100 across 970 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Accelerated Cure Project for Multiple Sclerosis is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18+ able to give or individuals younger than 18 with parental permission and able to give assent
  • willing to provide up to 110 ml (50 ml for \< 18 years old) of blood via venipuncture
  • experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON

Exclusion criteria

Exclusion Criteria:

  • history of blood borne pathogens
  • bone marrow transplant
  • clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON).
  • weight less than 37 pounds
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
3,226 participants (actual)

Groups and cohorts

  • Case
  • Control
06

Study locations

10 sites
07

References and documents

08

Updates

1 registry update since Sep 25, 2026
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00445367
Lead sponsor
Accelerated Cure Project for Multiple Sclerosis
Responsible party
Sponsor
First posted
Mar 9, 2007
Start date
May 2006
Primary completion
Oct 2030 (estimated)
Completion
Oct 2036 (estimated)
Last update
Oct 27, 2026

Study contacts

Benjamin Greenberg, M.D., M.H.S.
principal investigator · University of Texas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion